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A B S T R A C T   
Background: Cardiopulmonary exercise test (CPET) is indicated as part of the assessment in hypertrophic car-
diomyopathy (HCM) patients and stress echocardiography is often used to assess symptoms. However, the role of 
exercise testing for prognostic stratification in HCM is still not established. 
Aims: To systematically review the evidence on the role of exercise testing for prognostic stratification in hy-
pertrophic cardiomyopathy. 
Methods: A systematic review was conducted for eligible publications, between 2010 and 2020, that included 
evaluation of outcomes and prognosis. In these studies, patients underwent exercise echocardiography and/or 
cardiopulmonary exercise testing, performed according to predefined protocols. Diverse parameters were 
assessed in order to determine which were relevant for the prognosis. Analyzed outcomes included death from 
any cause, sudden cardiac death (SCD) and equivalents, cardiovascular death, heart failure requiring hospital-
ization or progression to New York Heart Association classes III or IV, cardiac transplantation, non-sustained 
ventricular tachycardia, stroke, myocardial infarction and invasive septal reduction therapy. 
Results: Eighteen publications were included, corresponding to a total of 7525 patients. The mean follow-up 
period varied between 1 and 8 years. The main findings of these studies revealed that the major predictors of 
outcomes were abnormal heart rate recovery, abnormal blood pressure response exercise induced wall motion 
abnormalities, lower peak VO2, higher VE/VCO2, and pulmonary hypertension/exercise-induced pulmonary 
hypertension. 
Conclusion: Although most studies concluded that exercise test results are useful to determine prognosis in HCM, 
further investigation is needed regarding whether it adds independent value to the current risk stratification 
strategies.   
1. Introduction 
Hypertrophic Cardiomyopathy (HCM) affects approximately 0.2% of 
the adult population worldwide. It is characterized by left ventricular 
hypertrophy (LVH) in the absence of another cardiac, systemic, or 
metabolic disease capable of producing the magnitude of hypertrophy 
seen; a causal sarcomere (or sarcomere-related) variant might be iden-
tified, or a genetic etiology may remain unresolved [1,2,3]. It is a cause 
of sudden cardiac death (SCD), heart failure (HF) and arrhythmias 
including atrial fibrillation [1]. 
Patients frequently present with reduced exercise capacity [1,2,3], 
which can be explained by diverse mechanisms, including left ventric-
ular outflow tract obstruction (LVOTO), myocardial ischemia and left 
ventricular systolic and diastolic dysfunction [1]. Chest pain is also a 
common presenting symptom. 
Cardiopulmonary exercise testing (CPET) is recommended as part of 
the initial evaluation of patients with a diagnosis of HCM, when they 
report change in symptoms or when considering therapy to reduce 
* Corresponding author at: Barts Heart Centre, St. Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom. 
E-mail address: luis.lopes1@nhs.net (L.R. Lopes).   
1 These authors contributed equally to the work and are joint first authors. 
Contents lists available at ScienceDirect 
International Journal of Cardiology 
journal homepage: www.elsevier.com/locate/ijcard 
https://doi.org/10.1016/j.ijcard.2021.06.051 
Received 16 May 2021; Received in revised form 21 June 2021; Accepted 28 June 2021   
International Journal of Cardiology 339 (2021) 83–92
84
LVOTO [1,2,3]. It allows the measurement of peak oxygen consumption 
(VO2), minute ventilation relative to CO2 production (VE/VCO2) slope, 
aerobic threshold (first ventilatory threshold - where the lactate pro-
duction rate is higher than the metabolizing capacity of the muscle cell) 
and anaerobic threshold (second ventilatory threshold – defined when 
the muscular lactate production rate exceeds the systemic lactate elim-
ination rate) [4,5]. It may clarify equivocal symptoms, evaluate func-
tional capacity prior to corrective therapeutic procedures, help 
distinguish between cardiac and pulmonary etiologies of functional 
impairment [1,6]. In addition, it was suggested it may allow a possible 
incremental prognostic role in the low-intermediate SCD risk categories 
over the contemporary strategies [3]. 
Exercise echocardiography allows evaluation of systolic anterior 
motion of the mitral valve, mitral regurgitation, left ventricular outflow 
tract (LVOT) or mid-cavity pressure gradients, diastolic and systolic 
function while on cycloergometer or treadmill exercise, providing 
valuable information to explain and assess the degree of severity of some 
of the symptoms [1,6]. 
Overall, ECG exercise testing, CPET and exercise echocardiography 
have been reported to predict multiple aspects of the prognosis in HCM 
patients. However, current guidelines do not incorporate any type of 
exercise testing for risk stratification strategies in HCM [1]. 
The aim of this work was to systematically review the current evi-
dence concerning the relevance of these three forms of exercise testing 
for prognostic assessment in hypertrophic cardiomyopathy. 
2. Methods 
2.1. Search strategy and study selection 
A systematic search was made on December 2020, using the Med-
line/PubMed and Embase databases, years 2010–2020, as well as 
searching for the publications included in the bibliography of the 
selected articles. The keywords used were: “prognosis AND (exercise OR 
stress OR cardiopulmonary) AND hypertrophic cardiomyopathy”. 
This systematic review of the literature was conducted using the 
methodology suggested by the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines [7]: a comprehensive 
search of the literature to identify all potentially relevant studies; sys-
tematic selection of studies based on inclusion and exclusion criteria; 
and extraction of relevant data from eligible studies. 
The following inclusion criteria were applied: prospective or retro-
spective studies; performed in humans; participants older than 18 years; 
published in English; study population fulfilling the diagnostic criteria 
for HCM; making use of electrocardiography, echocardiography or 
cardiopulmonary exercise tests; evaluation of outcomes and prognosis. 
Primary search was performed by two authors, who independently 
reviewed each reference (title and abstract) identified by the literature 
search, applied the inclusion and exclusion criteria listed above and 
decided on whether to include or exclude the publication at that stage. 
Any disagreement was solved by the senior author. 
2.2. Data extraction 
2.2.1. Patients and baseline assessment 
Inclusion of patients required a diagnosis of HCM based on guide-
lines criteria [1]. Baseline patient characteristics that were analyzed 
were: age [8–25]; the presence of cardiovascular symptoms (dyspnoea, 
pre-syncope, syncope, angina, palpitations) [8,10,11,13–24] or disease 
(coronary disease, hypertension, arrhythmia, valve disease) 
[8–12,14–16,20–22,24,25], as well as other systemic diseases (genetic, 
metabolic) that could cause myocardial hypertrophy 
[9,10,13,14,16,21]; family history of premature sudden death or HCM 
[8–12,14–17,21,24]; medication at the time of the study 
[8–12,14–16,20–25]; history of cardiac surgery and/or medical therapy 
to relieve LVOTO [9–11,15,21,25]; an adequate acoustic window 
[14,21] for echocardiographic studies and the ability and will to un-
dergo exercise testing [14,21]. 
Other relevant initial baseline assessments included New York Heart 
Association (NYHA) functional class of HF [8,9,11–13,15–24], 12‑lead 
ECG at rest [8,10,12,15,17,20] and 24 h-ECG [8]. 
2.2.2. Resting and exercise echocardiography 
In some studies [8–25], patients underwent resting transthoracic 
echocardiography, including M-Mode, bi-dimensional (2D) and, in some 
cases, Doppler evaluation, followed by symptom-limited exercise 
echocardiography in a treadmill in four studies [12,14,17,20,21]. 
Regarding exercise echocardiography [12,14,17,20–22], medica-
tions were not generally withdrawn before the test. Heart rate (HR) and 
blood pressure (BP) were measured during the test and afterwards, and 
ECG was monitored. 
2.2.3. Cardiopulmonary exercise testing 
In those studies in which patients were submitted to CPET 
[10,11,13–16,20,22,24], the tests were performed with regular HR and 
BP measurements and ECG monitoring, according to standard protocols 
(e.g. Bruce), with gas exchange measurement. 
Heart rate recovery (HRR), defined as a drop in heart rate (HR) from 
peak to 1 min post-exercise [26] was measured in two of the studies 
[12,15], to ascertain the fraction of patients with abnormal HRR (<12 
beat drop over 1 min in recovery). Abnormal BP response (defined as 
progressive hypotension or a failure to increase the systolic blood 
pressure > 20 mmHg during exercise [27]) was also recorded in eight 
studies [10–13,15,17,18,20,22,23]. 
2.2.4. Follow-up and outcomes 
Patients were followed up with a defined regularity, so as to deter-
mine the occurrence of events. Death certificates were also analyzed in 
three of the studies [12,14,22]. 
Primary outcomes of relevance were death from any cause 
[8–10,12,14,16,18,20,21,23], sudden death (defined as unexpected 
sudden collapse occurring <1 h from the onset of symptoms in patients 
who had previously experienced a relatively stable course [18,23,24].), 
death due to progressive HF or “other” [8,9,11,14,16,20,21,23], sudden 
death equivalents (successful resuscitation from cardiac arrest and 
appropriate implantable cardioverter defibrillator (ICD) discharge), 
heart failure (HF) requiring hospitalization [9,11,16,20,21] or pro-
gression from NYHA class I or II to class III or IV of HF and cardiac 
transplantation [14,15,20,23,24]. 
Secondary outcomes of relevance were sustained ventricular tachy-
cardia [8,12,14,18,21]; stroke in the context of atrial fibrillation (AF) 
[12,14,16,21]); myocardial infarction [14] and clinical deterioration 
leading to need of therapy to relieve LVOTO (including septal reduction) 
[14]. 
3. Results 
3.1. Study selection 
1368 unique publications were found and analyzed. 1236 of these 
publications were excluded for not fulfilling the age, date of publication 
and language criteria. The remaining 132 were analyzed by reading the 
abstract, and 114 of them excluded for not fulfilling the remaining 
criteria. Therefore, 18 studies were selected for this systematic review 
[8–25] (Fig. 1), corresponding to a total of 7525 patients. 
3.2. Design of the studies and baseline characteristics of the patients 
Most studies (16 out of 18) were single-centre and observational. 
Only two studies included over 1000 patients [15,17]. The mean follow- 
up was between 1.6 ± 0.95 years and 8.7 ± 3 years. Mean age of the 
patient populations varied between 44 ± 14 and 59 ± 21 years. A 
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Fig. 1. Study selection flow chart.  
Table 1 
Demographic characteristics of the patients.  








Family history of HCM, 
n(%) 
Efhtimiadis et al, 2010 [8] n =
68 
Thessaloniki, Greece 2007–2009 68 2 44.8 ± 14.6 45 (67.1) 32(47) 
Sorajja et al, 2012 [9] n = 182 Rochester (Minnesota), 
USA 
1991–2008 182 4 ± 3.2 53 ± 15 119 (65) 43(24) 
Peteiro et al, 2012 [10] n =
220 
A Coruña, Spain – 239 4.1 ± 2.6 52 ± 15 145 (61) 76(32) 
Reant et al, 2014 [11] n = 115 Bordeaux-Pessac, France 2009–2012 115 1.6 ± 0.95 51.9 ± 15.2 76 (66) 59(51) 
Desai et al, 2014 [12] n = 426 Cleveland (Ohio), USA 1997–2007 426 8.7 ± 3.0 44 ± 14 310 (73) 105(25) 
Finocchiaro et al, 2015 [13] n 
= 156 
Stanford (California), USA 2007–2012 156 2.25 ± 0.92 51 ± 14 96 (62) – 
Peteiro et al, 2015 [14] n =
148 
A Coruña, Spain – 148 7.1 ± 2.7 51 ± 15 97 (65.5) 44(29.7) 
Masri et al, 2015 [15] n =
1005 
Cleveland (Ohio), USA 1997–2012 1005 5.5 ± 4 50 ± 14 643 (64) 201(20) 
Feneon et al, 2015 [16] n =
126 
Rennes and Tours, France 2009–2013 126 2.4 ± 2.0 47.41 ±
15.48 
99 (78.1) 42(34.1) 
Coats et al, 2015 [17] n =
1898 
London, United Kingdom 1998–2010 1898 5.6 46 ± 15 1278 
(67) 
778(42) 
Ciampi et al, 2016 [18] n =
706 
Italy, Spain, Portugal and 
Serbia 
1984–2015 706 4.1 50 ± 16 381 (54) – 
Magri et al, 2016 [19] n = 623 Rome, Italy 2007–2015 623 3.7 49 ± 16 429 (69) – 
Moneghetti et al, 2017 [20] n 
= 131 
California, USA 2007–2012 131 4.6 52 ± 13 83 (63) – 
Lu et al, 2017 [21] n = 536 Baltimore, USA 2005–2015 536 2.1 52 ± 15 359 (67) 110(20.5) 
Rigopoulos et al, 2018 [22] n 
= 21 
Athenes, Greece 2005–2011 21 2.4 ± 1.08 48.8 ± 13.7 14 (67) – 
Smith et al, 2018 [23] n = 589 Michingan, USA – 589 4.3 ± 3.3 50.7 361 
(61.3) 
– 
Magri et al, 2018 [24] n = 681 Italia 2007–2017 681 4.2 48 ± 16 463 (68) 80 (12) 
Hamatani et al, 2019 [25] n =
42 
Osaka, Japan – 42 2 59 ± 21 14 (33) –  
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percentage between 33 and 78.1 were men, with a positive familial 
history of HCM present in at least 20% up to 51% of the study popula-
tion. Up to 22% of the patients were in class NYHA>II at baseline. Be-
tween 5% and 20.5% of patients had a diagnosis of AF and 20% to 42% 
had hypertension. The assessment and reporting of “classical” risk fac-
tors for sudden death, i.e. defined according to the 2003 ESC/American 
College of Cardiology (ACC) [1] and 2011 ACC/AHA (American Heart 
Association) guidelines [2] such as syncope, family history of SCD, non- 
sustained ventricular tachycardia (NSVT), abnormal BP response to 
exercise, and LV wall thickness ≥ 30 mm varied, but were generally 
present in less than 20% of the study population in almost all studies. 
The ESC clinical risk prediction model for sudden cardiac death in HCM 
patients considers eight different predictors (age, maximal left ventric-
ular wall thickness, left atrial diameter, left ventricular outflow tract 
gradient, family history of SCD, non-sustained ventricular tachycardia, 
and unexplained syncope) to provide individualized 5-year risk for 
sudden cardiac death. In the analyzed studies these characteristics were 
underreported, limiting calculation of this score for the studies pub-
lished after the score - and more recent European guidelines - were 
published [1,28]. The percentage of patients under β-blockade was be-
tween 33.1% and 90%. A minority of patients had, at baseline, a per-
manent pacemaker (5 to 21% of the population in the different studies) 
or an ICD (0 to 39% of the population). Baseline characteristics of the 
patients included in the studies are summarized in Tables 1 and 2; and 
supplementary Tables 1 and 2. 
3.3. Resting and exercise echocardiography 
Resting and exercise echocardiography main measurements are 
summarized in Table 3. Exercise echocardiography was the only exercise 
test performed in eight studies [10–12,14,16,18,21,25], and it was 
executed along with CPET in three other studies [8,13,15,20]. 
For resting echocardiography, maximal wall thickness was between 
17 ± 5 and 22 ± 6 mm. LVEF was preserved (>50%) in all studies, ac-
cording to the current reference values [29], and in general was mini-
mally (slight increase between 0 and 6% in 4 studies) or not changed 
with exercise. Mean LVOT pressure gradient at rest was >30 mmHg in 
six of the studies [9,11,15,21–23], which is diagnostic of LVOTO [2], 
and during exercise it was >50 mmHg in five studies [10,12,15,20,21]. 
When evaluated both at rest and during exercise it worsened by, at least, 
5 mmHg. Regional wall motion abnormalities (WMAs) appeared de novo 
or worsened with exercise in the three studies evaluating this parameter; 
this is around four times more patients, when compared with the same 
parameter evaluated on resting echocardiography [10,14,18]. Not all 
studies that evaluated mitral regurgitation (MR) at rest repeated this 
evaluation in exercise echocardiography and one study [16] only re-
ported it with exercise. MR at rest was present in between 10% and 
95.4% of patients in all studies evaluating this parameter and between 
24% and 93% of patients had MR during exercise, since it appeared de 
novo in some cases. In others, MR progressed to higher degrees of 
severity. Between 25% and 49.1% of patients had SAM at rest, defined as 
any contact of the leaflet with the septum during systole [11,12,15]. In 
the studies that also evaluated this parameter during exercise it was 
shown that it generally appeared in patients who did not have it at rest 
and worsened in the ones who had [12,15]. 
3.4. Cardiopulmonary exercise testing 
Cardiopulmonary exercise testing was performed in isolation in 
seven studies [8,9,17,19,21–24] and together with exercise echocardi-
ography in three [13,15,20]. Main measurements regarding CPET are 
summarized in Table 4. 
Among the evaluated parameters in CPET, peak VO2 and VE/VCO2 
were the ones that were consistently analyzed in all the studies that 
performed CPET, and also those that demonstrated a higher correlation 
with outcomes, as discussed below. Mean peak VO2 varied between 
17.7 ± 6 and 28.3 ± 8.7 and mean VE/VCO2 varied between 20 ± 17 
and 32.6 ± 7.3. In a study that compared HCM patients to a control 
population [20], it was shown that in the HCM population peak VO2 was 
lower and VE/VCO2 slope was higher than in controls. Percentage of 
predicted peak VO2 (generally based on age and sex) was <80% on 
average. 
3.5. Other resting and exercise parameters 
Other resting and exercise parameters are summarized in Table 5. 
Mean HRR was, in the two studies [8,12] that reported this param-
eter, over 12 beats per minute (bpm), the threshold below which is 
considered abnormal, although this parameter demonstrated to be 
Table 2 















al, 2010 [8] 





– – – 
Sorajja et al, 
2012 [9] n 
= 182 





Peteiro et al, 
2012 [10] n 
= 220 
90(38) – 32 
(13) 
– – – 
Reant et al, 
2014 [11] n 
= 115 





Desai et al, 
2014 [12] n 
= 426 






al, 2015 [13] 
n = 156 
– 22(14) – – – – 
Peteiro et al, 






– – – 
Masri et al, 
2015 [15] n 
= 1005 






Feneon et al, 




5(4) – 39 
(31.0) 
– – 
Coats et al, 
2015 [17] n 
= 1898 
757(41) 145(8) – – – – 
Ciampi et al, 
2016 [18] n 
= 706 
– 47(7) – – – – 
Magri et al, 
2016 [19] n 
= 623 
– 37(6) – – – – 
Moneghetti et 
al, 2017 [20] 
n = 131 
– 27(21) 24 
(18) 
– – – 
Lu et al, 2017 







– – – 
Rigopoulos et 
al, 2018 [22] 
n = 21 
10 (48) 15 (71) 1 (5) – – 4 
(19) 
Smith et al, 





– – – – 
Magri et al, 
2018 [24] n 
= 681 
– 37 (5) – 170 
(25) 
27 (4) 34 
(5) 
Hamatani et al, 
2019 [25] n 
= 42 
– – 6 (14) – – – 
AF: atrial fibrillation; CAD: coronary artery disease; HT: hypertension; NYHA: 
New York Heart Association functional class. 
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Table 3 







































al, 2010 [8] 












– – – – – – – 
Sorajja et al, 








– – – – – – – 
Peteiro et al, 
2012 [10] 
n = 220 
20 ±
5 
69 ± 9 73 ± 10 44 ±
7 
– 25 ± 32  
(LVOTO at 
rest, 
n (%) = 60 
(25)) 
50 ± 54  
>30 mmHg, 
n (%) = 103 
(43); 
>50 mmHg, 
n (%) = 83 
(35) 
5(2) 19(7.9) 40(17) 67(28) – – 
Reant et al, 
2014 [11] 














n (%) = 42 
(37) 





n (%) = 34 
(30)) 
– – 51(45) 49(43) 30 
(26) 
– 
Desai et al, 
2014 [12] 
n = 426 
20 ±
5 
61 ± 5 – 42 ±
8 






















n (%) = 54 
(35)) 
– – 15(10) – – – 
Peteiro et al, 
2015 [14] 
n = 148 
20 ±
5 










30 mmHg, n 
(%) = 66 
(45)) 
3(2) 13(9) 23 
(15.5) 
36(24) – – 
Masri et al, 
2015 [15] 
n = 1005 
21 ±
5 
62 ± 6 – 44 ±
24 





Feneon et al, 
2015 [16] 
n = 126 







rest > 50 
mmHg, 







n (%) = 16 
(12.7)) 
– – – 22(20.9) – – 
Coats et al, 
2015 [17] 
n = 1898 
19 ±
5 
65 ± 11 – 44 ±
8 
– – – – – 221 
(12) 
– – – 
Ciampi et al, 
2016 [18] 
n = 706 
20 ±
5 










50 mmHg, n 
(%) = 116 
(20) 
– 35(6) 92(13) – – – 
Magri et al, 
2016 [19] 
n = 623 
20 ±
5 
63 ± 7 – 42 ±
7 









rest n (%) 
= 41(31) 
57 ± 52 – – 48(37) – – – 
22 ±
6 




80 ± 39.3 – – – – – – 
(continued on next page) 
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relevant in terms of prognosis, as discussed below. Abnormal BP 
response, which has been considered a risk factor for SCD, occurred in 
between 1% and 43% of the patients. 
3.6. Follow-up and outcomes 
Adverse events during follow-up were previously defined (see 
methods). The main predictors of worse outcomes were abnormal HRR 
[12], chronotropic incompetence [8,24], abnormal blood pressure 
response [23], AF at rest [12], low global longitudinal strain on echo-
cardiogram [11], high left atrium volume [13], exercise WMAs [10,14], 
higher VE/VCO2 slope, lower peak VO2 [13,17] and pulmonary hy-
pertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 
mmHg at rest /exercise-induced pulmonary hypertension (EIPH) 
defined as pulmonary artery systolic pressure ≥ 60 mmHg during ex-
ercise [25]). The primary endpoints of most studies were combined and 
highly variable between the different publications. Table 6 summarizes 
the outcome data. 
3.7. Limitations of the included studies 
The limitations were common to the majority of the studies and 
included studies being performed by only one centre [16], mostly 
referral centres for HCM, which means that the sample might not have 
been representative of the overall HCM population [8,12,13]. Addi-
tional selection biases were present, such as only including patients who 
were able to undergo exercise echocardiography [12] and exclusion of 
patients in NYHA class IV and with a prior LVEF<50%. It was also noted 
either a tendency to include more symptomatic patients, because of 
clinical indication, in some studies [8,13,17] or, in one study, not 
including more symptomatic patients, since they were referred to sur-
gery before undergoing stress testing [14]. Another limitation of some of 
the included articles was a small sample size [8,22,25]. 
In some of the studies, the patients did not withdraw medications 
(because it was considered unethical), such as beta-blockers and calcium 
channel blockers, which obviously influenced the hemodynamic 
response to exercise, diminishing the accuracy of defining an abnormal 
BP response, an abnormal chronotropic response and blunting the 
exercise-induced LVOT gradient [11,16]. 
Many studies were limited due to having a short follow-up period 











































[22] n = 21 
19.7 
± 4.5 




– . . 15(71) – – – 
Smith et al, 
2018 [23] 
n = 589 
18.8 
± 4.9 
– – – – 38.1 
(LVOTO at 
rest, n (%) 
= 339 
(57.5)) 
. . . – – – – 
Magri et al, 
2018 [24] 
n = 681 
20 ±
5 
63 ± 6 – 42 ±
7 





– – – – – – – 
Hamatani et 
al, 2019 
[25] n = 42 
18 ±
4 




10 (5–18) 29 (12–62) – – 7 (17) 15 (36) – – 
LAD: left atrial diameter; LAiV: left atrial indexed volume; LVEF: left ventricular ejection fraction; LVOT: left ventricular outflow-tract; LVOTO: LVOT obstruction; 
MWT: maximal wall thickness; RWMAs: regional wall motion abnormalities; MR: mitral regurgitation; SAM: systolic anterior motion of the mitral valve; SD: standard 
deviation. *mean ± SD or median (interquartile range). 
Table 4 





% of Predicted 











al, 2010 [8] 
n = 68 
28.3 ±
8.7 
79.1 ± 27.5 27.3 ±
4.6 
21.8 ± 6.9 1.16 
±
0.11 
Sorajja et al, 


















Masri et al, 
2015 [15] n 
= 1005 
21 ± 6 (Peak VO2 <
50%, n(%) =
150(15)) 
20 ± 17 – 1.09 
±
0.17 
Coats et al, 




67 ± 21 32.6 ±
7.3 
11.7 ± 4.2 1.10 
±
0.11 
Magri et al, 
2016 [19] n 
= 623 




















[22] n = 21 
17.7 ±
4.8 
66.4 ± 18.7 31.6 ±
5.6 
11.1 ± 3.6 1.1 
± 0.1 
Smith et al, 
2018 [23] n 
= 589 
– 76.5 ± 22.4 – – 1.13 
± 0.1 
Magri et al, 




72 ± 20 – – – 
Peak VO2: peak oxygen consumption; VE / VCO2: ventilation/carbon dioxide 
output; RER: respiratory exchange ratio. 
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[11,13,21,25] and/or a reduced number of events [11,13,14,16]. 
Finally, some of the parameters were not uniformly assessed and 
hence not reported [12], which related to the fact that exercise echo-
cardiography protocols are not standardized in HCM (some are per-
formed in treadmill and others in semi-supine position, and the latter 
tends to require lower workload). Therefore, it might be challenging to 
compare different works. 
Some of the studies were performed by the same authors and at the 
same centre, so there might be some overlap of study populations. 
In general, the heterogeneity of the methods, reported parameters 
and outcomes precluded a meta-analysis. 
A Downs and Black checklist is provided in supplementary material. 
4. Discussion 
We hereby present an up to date systematic review of contemporary 
studies evaluating the prognostic value of exercise testing in HCM and 
report a group of parameters, obtained from either exercise echocardi-
ography or cardiopulmonary exercise testing, that revealed to be pre-
dictors of worse outcomes. 
These parameters are summarized in Fig. 2. 
Exercise testing, either echocardiographic or cardiopulmonary, al-
lows the evaluation of diverse clinically relevant parameters in the 
assessment of HCM patients. The role of exercise testing is well defined 
for symptom evaluation and management. However, its utility in the 
prediction of outcomes, in order to obtain a more accurate risk strati-
fication and improve the prognostic models, is less well established. 
The relevance of performing exercise echocardiography to study 
LVOTO during exercise was firstly reported in 2006 [30] but only few 
groups have investigated the prognostic implications. The data corre-
lating peak VO2 and other parameters obtained from cardiopulmonary 
exercise testing and prognosis have also been scarce. 
As expected, some of the parameters evaluated both at rest and with 
exercise echocardiography in the included studies, including SAM, 
LVOTO and MR, appeared de novo or worsened with exercise, due to the 
cardiac response to stress. 
Correlation of exercise-evaluated parameters with events was the 
main aim of this systematic review. One of these parameters was an 
abnormal HRR [8,12], possibly explained by a blunted vagal reac-
tivation in HCM patients [8], and might identify patients with a higher 
risk of death, malignant arrhythmias and HF progression. 
Abnormal BP response to exercise [11] has been previously consid-
ered a risk factor for SCD, although not included in the risk score eval-
uation from the latest ESC guidelines [1]. It was correlated with worse 
outcomes regarding heart failure hospitalization and with no increase in 
sudden cardiac death; this association was independent of LVOTO [28]. 
Abnormal BP response to exercise seemed to be a clinical indicator of a 
lack of cardiac reserve, rather than an independent risk factor for SCD. 
Exercise echocardiogram is also relevant to identify important sub-
groups of patients without gradients at rest (or with Valsalva) who 
nevertheless developed hemodynamically significant LV outflow 
obstruction only with exercise, including some with severe gradients, 
>50 mmHg. Indeed, a substantial proportion of these patients have 
limiting heart failure symptoms; therefore, identification of latent, 
exercise-triggered obstruction not only defines the probable mechanism 
for such symptoms but in many cases also reveals options for their relief 
with surgical or interventional septal reduction therapies [30]. 
AF in patients with HCM is considered to be a risk factor for car-
diovascular death, heart failure, and stroke [31,32]. However there are 
no data regarding the prognostic impact of AF induced by exercise. 
Regional exercise WMAs [10], probably explained by myocardial 
ischemia, were associated with a worse prognosis for HCM patients 
Table 5 
Other resting and exercise parameters.  
Study Heart rate at 
rest, bpm 
Peak heart rate, 
Bpm 
HRR, bpm or % of patients 
with abnormal HRR 
Systolic BP at 
rest, mmHg 
Peak systolic BP, mmHg ABPR, n 
(%) 
Efhtimiadis et al, 2010 
[8] n = 68 
74.9 ± 14.9 150.5 ± 24.5 – 123.9 ± 16.9 162.1 ± 29.9 – 
Sorajja et al, 2012 [9] n 
= 182 
71 ± 14 135 ± 27 – 120 ± 18 153 ± 38 – 
Peteiro et al, 2012 [10] 
n = 220 
– 144 ± 28 – – 161 ± 31 99(41) 
Reant et al, 2014 [11] n 
= 115 
67 ± 11 127 ± 23 – 132 ± 20 168 ± 31 17(15) 
Desai et al, 2014 [12] n 
= 426 
– 150 ± 26 31 ± 14 – 168 ± 35 5(1.2) 
Finocchiaro et al, 2015 
[13] n = 156 
68 ± 13 139 ± 27 – 118 ± 20 222 ± 78 – 
Peteiro et al, 2015 [14] 
n = 148 
– 147 ± 27 – – 160(140–180) 50(34) 
Masri et al, 2015 [15] n 
= 1005 
– 136 ± 26 - 
(Abnormal HRR, n(%) = 231 
(23)) 
– – 10(1) 
Coats et al, 2015 [17] n 
= 1898 
71 ± 15 138 ± 30 – 126 ± 21 71 ± 35 406(21) 
Ciampi et al, 2016 [18] 
n = 706 
– – – – – 141(23) 
Magri et al, 2016 [19] n 
= 623 
– - 
(% of predicted =
81 ± 14) 
– – - 
(difference between systolic BP with 
exercise and at rest,mmHg = 44 ± 24) 
– 
Moneghetti et al, 2017 
[20] n = 131 
67 ± 12 138 ± 29 – 119 ± 19 158 ± 27 5(4) 
Rigopoulos et al, 2018 
[22] n = 21 
– – . – – 9 (43) 
Smith et al, 2018 [23] n 
= 589 
– – – – 152.2 ± 24 192 (33) 
Magri et al, 2018 [24] n 
= 681 
74 ± 15 131 ± 26 – – – – 
Hamatani et al, 2019 
[25] n = 42 
64 ± 10 112 ± 22 – 128 ± 23 167 ± 22 – 
ABPR: abnormal blood pressure response; HRR: Heart Rate Recovery; BP: blood pressure; bpm: beats per minute. 
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[14,33], having incremental prognostic value over clinical and resting 
echocardiographic variables. 
Lower peak VO2 (as well as lower percentage of predicted peak VO2) 
and higher VE/VCO2 slope, that reflects ventilatory inefficiency, are 
parameters of exercise intolerance and associated with a worse prog-
nosis [13,17,20]. However, two of the studies [13,17] concluded that 
these were only related with some of the outcomes, namely heart failure 
and heart transplantation, and not with sudden cardiac death, probably 
because mechanisms for ventricular arrhythmia and loss of contractile 
function are different, suggesting the importance of defining prediction 
parameters for specific outcomes. The largest study [17] concluded that 
CPET was useful for the risk stratification of patients with both 
obstructive and non-obstructive forms of the disease. Lower anaerobic 
threshold was not as much predictive of worse outcomes as peak VO2 
and VE/VCO2. 
Exercise capacity reflected as NYHA class is part of the criteria used 
to refer a patient to invasive septal reduction therapy, but a specific VO2 
value/threshold is not currently used in this regard [1]. Recently Alashi 
et al [34] suggested that earlier myomectomy by surgery guided by VO2 
had better long term survival, raising a new topic for discussion. 
PH and/or EIPH appear to be the consequence of the increase of LV 
filling pressure secondary to diastolic dysfunction, LV obstruction, or 
mitral regurgitation, which could promote the occurrence of ventricular 
tachycardia [24]. Moreover, increased LV filling pressure results in 
atrial overload and remodeling, which might promote the occurrence of 
HF and AF. Indeed, PH in HCM patients was significantly associated with 
increased morbidity and EIPH also showed a significant association with 
HCM-related morbidity, perhaps because EIPH represents the down-
stream effect of the hemodynamic derangements that increase LV filling 
pressure during exercise [25]. 
Some of the assessed parameters were not consistently considered 
predictors of outcomes by all the studies. For example, indirect indices of 
diastolic dysfunction, such as LA diameter, were considered a predictor 
in two studies [13,16], but not in another one [10]. 
Severity and worsening of LVOTO (i.e. higher LVOT gradient at peak 
exercise) was predictive of outcomes in two studies [9,16], as well as in 
previous work [30,6], and not associated with events in two other 
[12,14]. One of the studies pointed out that peak LVOT gradient ≥50 
mmHg was more predictive of outcomes than rest LVOT gradient ≥30 
mmHg and that peak LVOT gradient was a better predictor than post- 
exercise measurement [11]. There is still conflicting evidence regarding 
the prognostic impact of exercise-induced LVOTO in HCM. 
MR has been described in patients with HCM since the first reports of 
the disease and it is commonly associated with LVOTO and SAM. Since it 
is a dynamic phenomenon, it is important to evaluate this parameter 
during exercise. Exercise-induced MR was associated with adverse car-
diovascular events in two studies [11,16], although in one of them [16] 
the result was not considered significant. As such, the increase in the 
degree of MR and its appearance de novo with exercise also seems to be 
of prognostic relevance. 
Chronotropic incompetence (i.e. a blunted increase in heart rate 
during exercise, defined as a maximal HR during exercise that is less 
than 65–80% of the predicted value) is a predictor of clinical outcome in 
Table 6 
Predictors of outcomes.  
Study Composite endpoint (CE) Predictor of outcome 
Desai et al, 2014 
[12] n = 426 
Death, appropriate ICD 
discharges, resuscitated 
sudden death, and admission 
for CHF  
• Abnormal heart rate 
recovery at 1 min in 
recovery: HR 0.89 
(0.82–0.97), p 0.007 - > 35 
vs 8% (p < 0.001) meeting 
the CE  
• Atrial fibrillation: HR 2.73 
(1.30–5.74), p 0.007 - >29 
vs 10% (p < 0.001) meeting 
the CE 
Efhtimiadis et al, 




ventricular fibrillation, and 
ICD discharge  
• Chronotropic incompetence 
group - low heart rate 
reserve (53.0 ± 4.0 bpm) - 
> 15 vs 0% (p 0.05) meeting 
the CE 
Magri et al, 2018 
[24] n = 681 
HF endpoint (death from HF, 
cardiac transplantation, 
progression to NYHA class 
III–IV,admission for CHF, and 
septal reduction procedure)  
• pHR equal to 70% as the 
best cut-off value in pre-
dicting the HF end-point HR 
2.9 (p < 0.001) (sensitivity: 
62%; specificity: 72%; AUC: 
0.68) 
Arrhythmia endpoint (SCD, 
aborted SCD and appropriate 
ICD shock)  
• pHR% equal to 65% as the 
best cut-off value in pre-
dicting the SCD end-point 
(sensitivity: 40%; speci-
ficity: 80%; AUC: 0.56) 
Smith et al, 2018 
[23] n = 589 
HF endpoint (first heart 
failure hospitalization)  
• ABPR at baseline testing 
were more likely to have a 
subsequent heart failure 
hospitalization (p = 0.002). 
The presence or absence of 
LVOTO did not alter this 
association. 
Arrhythmia endpoint (SCD, 
aborted SCD and appropriate 
ICD shock)  
• The adverse arrhythmia 
endpoint was not associated 
with ABPR (p = 0.270) 
Reant et al, 2014 
[11] n = 115 
Death related to HCM (SCD, 
death from HF, or stroke 
related to AF), SVT, 
appropriate cardiac shock or 
resuscitated cardiac arrest, 
and progression NYHA III or 
IV  
• Global longitudinal strain 
<15%, HR 3.29 (P = 0.028); 
(sensitivity of 67%, 
specificity of 77%, and AUC 
0.754) 
Peteiro et al, 
2012 [10] n =
220 
Cardiac death, cardiac 
transplantation, appropriate 
ICD shock, SVT, stroke 
related to AF, myocardial 
infarction, and HF requiring 
hospitalization  
• Exercise WMAs were more 
frequent in patients who 
developed hard events 
(31.5% vs 5.9%, P < 0.001) 
Peteiro et al, 
2015 [14] n =
148 
Cardiac death, cardiac 
transplantation, appropriate 
ICD shock, SVT, stroke 
related to AF, myocardial 
infarction, and HF requiring 
hospitalization  
• Exercise WMAs were more 
frequent in patients who 
developed hard events (57 
vs. 6%, P < 0.001) 
Finocchiaro et al, 
2015 [13] n =
156 
Overall mortality, heart 
transplantation, and 
functional deterioration 
leading to hospitalization for 
septal reduction  
• Peak VO < 80% of predicted 
(HR: 4.11; 95% confidence 
in- terval [CI]: 1.46 to 
11.59; p 0.008)  
• VE/VCO slope > 34 (HR: 
3.14; 95% CI: 1.26 to 7.87; p 
0.014)  
• Left atrial volume > 40 ml/ 
m2 (HR: 3.32; 95% CI: 1.08 
to 10.16; p 0.036) 
Coats et al, 2015 
[17] n = 1898 
All-cause mortality or cardiac 
transplantation.  
• Peak V̇O2 (adjusted HR 
0.85, 95% CI 0.77–0.92, P 
< 0.001) and VĖ V̇CO2 
slope (adjusted HR 0.85, 
95% CI 0.77–0.92, P <
0.001) were both 
independent predictors of 
the CE  
Table 6 (continued ) 
Study Composite endpoint (CE) Predictor of outcome 
Hamatani et al, 
2019 [25] n =
42 
SVT, hospitalization due to 
HF, and AF events (new-onset 
AF or hospitalization due to 
AF such as cardioversion)  
• EIPH had a significantly 
higher incidence of HCM- 
related morbidity than those 
without EIPH (log-rank; P =
0.01) 
ICD: implantable cardiac defibrillator; CHF: chronic heart failure, pHR: 
maximum age-predicted heart rate; SCD: sudden cardiac death; HF: heart fail-
ure; AUC: area under the curve; AF: atrial fibrillation; SVT: sustained ventricular 
tachycardia; WMA: wall motion abnormalities; EIPH: exercise-induced pulmo-
nary hypertension. 
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coronary artery disease, congenital heart disease and healthy pop-
ulations [35–37]. In HCM, it is possibly explained by autonomic 
dysfunction, sino-atrial electrophysiological remodeling, altered beta- 
receptors function and density as well as impaired intracellular cal-
cium signaling and was considered an independent predictor of exercise 
intolerance in one study [8], and an independent predictor of heart- 
failure related events in another study [24] – defined as a single exer-
cise derived parameter. 
In supplementary Table 3 we summarize all the current recommen-
dations regarding the various forms of exercise stress testing in HCM, 
comparing 2014 ESC guidelines and 2020 AHA/ACC guidelines [1,3]. 
5. Conclusion 
Data derived from exercise, which can be assessed with exercise 
echocardiography and/or cardiopulmonary exercise testing, is able to 
objectively evaluate functional status but also to risk stratify HCM pa-
tients, refining prognostic assessment. Further investigation in this area 
is warranted, namely larger, multi- center studies with longer follow-up 
and standardized stress protocols to evaluate whether exercise testing 
adds independent value to the current risk stratification strategies in 
HCM. 
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